Not available
Quote | Ascendis Pharma A/S (NASDAQ:ASND)
Last: | $133.75 |
---|---|
Change Percent: | -0.82% |
Open: | $135.48 |
Close: | $133.75 |
High: | $136.36 |
Low: | $132.99 |
Volume: | 175,736 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Ascendis Pharma A/S (NASDAQ:ASND)
2024-07-16 09:45:00 ET Summary With inflation slowing in many countries, equity markets saw modest returns in Q2. In a cooling equity market, the portfolio fell short of the MSCI EAFE Index and the MSCI All Country World ex USA Index in Q2. Our holdings in the materials sector...
2024-07-04 12:56:50 ET More on Ascendis Pharma An Update On Ascendis Pharma's Path To Profitability Ascendis Pharma says FDA has delayed TransCon PTH review Ascendis Pharma reports Q1 results Seeking Alpha’s Quant Rating on Ascendis Pharma Re...
Message Board Posts | Ascendis Pharma A/S (NASDAQ:ASND)
Subject | By | Source | When |
---|---|---|---|
Short today at 85.34 | MiamiGent | investorshub | 05/01/2023 8:42:43 PM |
Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric | crudeoil24 | investorshub | 08/25/2021 9:19:58 PM |
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, | crudeoil24 | investorshub | 08/25/2021 9:17:30 PM |
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...